A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Amgen

Status: Completed

Conditions: Nephrology

Treatments: Drug: Sensipar®

Study type: Observational

Funder types: Industry

Identifiers

NCT00189501

20040159

Details and patient eligibility

About

Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• 3 month history of Stage 4 or Stage 5 CKD
• A PTH value within 3 months of enrollment
• If relevant, completion of Sensipar® study prior to enrolling in Registry Exclusion Criteria:
• Females who are pregnant or breast feeding